Sign In
Last checked at 
4 Jun 2014 13:52
Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)
Director's Shareholding
London: Wednesday, 4 June 2014: Chi-Med received notification on 3 June 2014 that Mr Christopher Nash, Independent Non-executive Director of Chi-Med, purchased 4,036 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of GBP8.42 each on3 June 2014.
Following this purchase, Mr Nash is beneficially interested in 30,542 Shares, representing approximately 0.06% of the current issued share capital of Chi-Med.
Ends
Enquiries
Chi-Med Christian Hogg, CEO | Telephone: +852 2121 8200 |
Panmure Gordon (UK) Limited Richard Gray Andrew Potts
| Telephone: +44 20 7886 2500
|
Citigate Dewe Rogerson Anthony Carlisle David Dible | Telephone: +44 20 7638 9571 Mobile: +44 7973 611 888 Mobile: +44 7967 566 919 |
About Chi-Med
Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.
Chi-Med (LSE:HCM) is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: www.chi-med.com.
Follow the stocks
